US FDA to review AI-based tool to predict drug-related liver damage

• Drug-induced liver damage is a major cause of trial failures, and current methods do not reliably predict human risk before clinical trials begin
• The AI-driven digital liver model assesses toxicity risk in new small-molecule drugs by comparing their chemical structures with existing medicines that have known safety profiles
• Acceptance into the Drug Development Tool qualification program marks the first step toward potential approval, which would allow pharmaceutical companies to use the tool in official regulatory submissions to the FDA

Summary: FDA to Review AI Tool for Predicting Drug-Induced Liver Damage

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) announced on June 3 that it has accepted a letter of intent to review an artificial intelligence-based tool designed to predict drug-induced liver injury during development.

Key Details:

The AI-driven digital liver model has been admitted to the FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program. The tool assesses liver toxicity risk in new small-molecule drugs by comparing their chemical structures against existing medicines with known safety profiles.

Market Significance:

Drug-induced liver damage is a major cause of clinical trial failures, and current testing methods inadequately predict human risk. This AI tool could improve early safety assessments, reduce animal testing reliance, and support better-informed decisions before initiating human trials.

Michael Davis, CDER's acting director, emphasized that "new technologies are showing incredible promise in helping improve and streamline drug development, with the ultimate goal of enhancing patient care."

Regulatory Process:

The acceptance represents the first step in a multi-stage qualification process. If approved, pharmaceutical companies could incorporate the tool into regulatory submissions. The FDA's Drug Development Tool qualification program evaluates whether tools meet standards for specific regulatory uses, with the letter of intent being the initial submission stage.

Industry Impact:

Successful qualification of this AI tool could accelerate drug development timelines, reduce costly late-stage trial failures, and potentially lower development costs across the pharmaceutical sector by enabling earlier identification of liver toxicity risks.